Drug Information Association Conference To Present Latest Strategies In Clinical Trial Disclosure Compliance

Main Category: Clinical Trials / Drug Trials
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 18 Sep 2008 - 6:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Experts from government, the pharmaceutical and biotech industries, and medical device companies will discuss best practices to ensure compliance with clinical trial disclosure laws and regulations, the Clinical Trials.gov registry, and results database during the Drug Information Association's (DIA's) Current Advancements in Clinical Trial Disclosure: The Changing Tide (October 15-16; Chicago, IL).

This follow-up to the successful 2007 Clinical Trial Disclosure Workshop will feature myriad topics, including:

- Challenges with journal requirements and legislation
- Academic and independent investigator compliance
- EMEA systems, requirements and developments
- Registries and results database requirements in the international community
- Company processes to handle disclosure activities
- Legislative actions and reactions

About the Drug Information Association (DIA)

DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, and Mumbai, India, the Association is led by its volunteer-based Board of Directors and executive management team.

Drug Information Association